Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Oncology

12 Health Care Stocks Moving In Monday's Pre-Market Session

Benzinga

Nurse, 24, whose 'clumsiness' and short temper turned out to be brain tumour

Fern Cameron, 24, noticed her mood was changing and she was getting more short-tempered and easily wound up, she was referred for an MRI scan which revealed a brain tumour

Daily Mirror

Stocks That Hit 52-Week Lows On Friday

On Friday, 1043 companies hit new 52-week lows.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Recap: Sierra Oncology Q1 Earnings

Sierra Oncology (NASDAQ:SRRA) reported its Q1 earnings results on Friday, May 6, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Guardant Health Clocks 22% Jump In Q1 Revenues, Reiterates FY22 Guidance

Guardant Health Inc's (NASDAQ:GH) Q1 FY22 revenues rose 22% Y/Y to $96.1 million, beating the consensus of $95.70 million. Guardant's precision oncology testing revenues grew 32% to $84.1 million, driven by the increase in clinical and biopharma testing. Development services and other revenues rose 20% to $12.0 million from $14.9 million in…

Benzinga

Illumina Reports 41% Dip In Q1 Profits Despite 12% Jump in Sales, Reaffirms FY22 Guidance

Illumina Inc's (NASDAQ:ILMN) Q1 FY22 revenues rose 12% Y/Y to $1.22 billion, in line with estimates. Nearly all revenues came from the core Illumina business; GRAIL, Illumina's cancer liquid biopsy subsidiary, recorded revenues of $10 million. Product revenue for the quarter totaled $1.07 billion, up 12%, and Service and other revenue amounted to…

Benzinga

Jazz Pharma Reports Q1 Epidiolex Sales Increased 6% To $157.9M YoY

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2022.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

FDA Accepts AstraZeneca's sBLA for Imfinzi (durvalumab) in biliary tract cancer (BTC) with Priority Review

The U.S. Food and Drug Administration (FDA) has accepted AstraZeneca's (NASDAQ: AZN) supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy and granted Priority Review for patients with locally advanced or metastatic biliary tract cancer (BTC).

Benzinga

Clovis Oncology: Q1 Earnings Insights

Clovis Oncology (NASDAQ:CLVS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

Earnings Scheduled For May 4, 2022

Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.

Benzinga

Labor pledges cancer radiation centre for NSW Far South Coast but locals sceptical

Unlike their city counterparts, having access to essential cancer treatments is merely a dream for many on the NSW far south coast. And despite political promises, some fear that dream may never become a reality.

ABC News

12 Health Care Stocks Moving In Monday's Intraday Session

Benzinga

Andhra Pradesh: APSRTC ties up with corporate hospitals for services to employees

VIJAYAWADA

The Hindu

Why These Analysts Are Bullish On Gilead's Q1 Earnings

RBC Capital Market views Gilead Sciences Inc's (NASDAQ:GILD) Q1 as a solid quarter, with a bottom-line beat reflecting Veklury cash flow boost, solid core business performance despite seasonal headwinds, and in-line operating expenses. The analyst notes that the story remains somewhat catalyst light, especially with transformative M&A likely off the table. HIV sales,…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

AbbVie Shares Fall On Mixed Bag Q1 Results, Cuts FY22 Profit Guidance

AbbVie Inc (NYSE:ABBV) reports Q1 adjusted EPS of $3.16, higher than the $2.89 reported a year ago and beating the consensus of $3.14. Overall sales increased 4.1% Y/Y (5.4% on an operational basis) to $13.54 billion, missing the consensus of $13.63 billion. The immunology portfolio generated $6.14 billion in sales, +6.9% (+8.1%…

Benzinga

AstraZeneca Clocks Q1 COVID Vaccine Sales Of $1.2B, Keeps Overall FY22 Outlook

AstraZeneca Plc's (NASDAQ:AZN) total revenue jumped 60% Y/Y at CER to $11.39 billion in Q1 FY22, beating the consensus of $10.99 billion. The growth reflects the contribution of the Alexion medicines and several Vaxzevria contracts that are expected to complete the delivery by half year 2022. Core EPS came in at $1.89,…

Benzinga

Stocks That Hit 52-Week Lows On Thursday

During Thursday, 849 stocks hit new 52-week lows.

Benzinga

Merck Clocks 50% Q1 Sales Growth Boosted By COVID-19 Treatment, Tightens FY22 EPS Outlook

Merck & Co Inc's (NYSE:MRK) Q1 sales reached $15.90 billion, +50% Y/Y, beating the consensus of $14.68 billion. Excluding the foreign exchange impact, revenues were up 52%. Pharmaceutical sales increased 53% to $14.11 billion, primarily driven by molnupiravir, oncology, vaccines, and hospital acute care products. Pharmaceutical sales growth, excluding Lagevrio sales, was…

Get all your
news in one place.

100’s of premium titles.
One news app.

Miami Herald

‘I just need a space to cry.’ How hospitals have set up places where nurses can recharge

MIAMI -- Caring for very sick children daily can be emotionally taxing, even for professionals with years of experience. As front-line workers who also support grieving parents, nurses often cope with chronic stress.

Benzinga

Stephens & Co. Maintains Equal-Weight Rating for Universal Health Services: Here's What You Need To Know

Stephens & Co. has decided to maintain its Equal-Weight rating of Universal Health Services (NYSE:UHS) and lower its price target from $150.00 to $135.00. Shares of Universal Health Services are trading down 0.72% over the last 24 hours, at $124.42 per share.

Benzinga

Stocks That Hit 52-Week Lows On Wednesday

Wednesday's session saw 784 companies set new 52-week lows.

Benzinga

Non-COVID Sales Boost Exact Sciences' Q1 Revenue; Revises FY22 Guidance

Exact Sciences Corp's (NASDAQ:EXAS) Q1 revenues increased 21% Y/Y to $486.6 million, beating the average Wall Street estimate of $461.71 million. Excluding COVID-19 testing revenues, which dropped 15% to $27.4 million, Exact's Q1 revenue increased 24%. Screening revenues rose 28% to $306.5 million in Q1, while Precision Oncology revenues were up 18%…

Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers

Benzinga

Stocks That Hit 52-Week Lows On Thursday

On Thursday, 236 companies hit new 52-week lows.

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Brain Tumour Research

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.